Phase 3 N=1,532 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001
Phase 3 N=1,115 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001
Phase 3 N=2,028 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival Rate (10-year) — 61.9; 56.8 percentage of patients — p=0.0309
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Phase 2 N=204 Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
Adenocarcinoma of the Prostate · Stage II Prostate Cancer
Primary: Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at…
Phase 2 N=27 Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Prostate Cancer
Primary: Toxicity — 2; 0 Events
Phase 2 N=32 Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants
Phase 3 N=840 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Prostate Cancer
Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=80 Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Prostate Cancer
Primary: Number of Participants Free From Progression at 3 Years — 54 participants
Phase 3 N=3,040 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 5.8; 5.1 years — p=0.15
Phase 2 N=15 Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
Prostate Cancer
Primary: PSA Response Rate — 15.4 percentage of participants
N/A N=5 Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
Stage I, IIA and IIB Seminoma
Primary: Number of Serious Adverse Events — 0 Participants
Phase 2 N=95 Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Prostate Cancer
Primary: Number of Participants With a Response — 12; 13 participants
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 2 N=5 Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events
Phase 3 N=961 S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 87; 86 percentage of probability of survival — p=0.70
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 2 N=36 Phase II Sunitinib Prog Met AIPC
Metastatic Prostate Cancer
Primary: Median Progression-free Survival (PFS) Time at 1-year. — 19.4 weeks
N/A N=116 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
Prostate Cancer · Sexual Dysfunction · Sexuality and Reproductive Issues
Primary: Erectile Dysfunction Rates — 27; 36 Participants
Phase 2 N=99 Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
Prostate Cancer
Primary: 2-year Metastasis-Free Survival Rate — 42.3; 41.8 percent probability — p=0.97
Phase 2 N=57 Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 2 N=36 Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Phase 2 N=255 Radiation Therapy in Treating Patients With Prostate Cancer
Prostate Cancer · Psychosocial Effects of Cancer and Its Treatment · Radiation Toxicity
Primary: Percentage of Patients With Reduction From Baseline to the One-year EPIC Bowel Domain Score That Exceeds 5 Points — 30.1; 28.0 percentage of participants — p=0.19
Phase 2 N=41 S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Progression-free Survival — 13 months